Author

Jaejun Lee

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five-Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD.

BACKGROUND/AIMS Genetic variants in PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13 have been associated with MASLD progression and hepatocellular carcinoma (HCC). We evaluated their associations with prevalent HCC and the performance of a five-variant polygenic risk score (PRS-5) in Korean patients with MASLD. METHODS A...

Jaejun Lee, J. Cha, Hee Sun Cho et al. · Journal of Gastroenterology... · 0 citations

Meta-analysis Open access Sep 2026

Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis

Background/purpose Atezolizumab–bevacizumab (AB) and durvalumab–tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain. Methods We included 76 observational reports comprising 10,243 patients. Report-level median surviv...

Jongin Lee, K. Tak, Hee Sun Cho et al. · Frontiers in Immunology · 0 citations

Open access Sep 2026

Dose–response relationship between tea consumption and mortality, cardiovascular, cerebrovascular, and renal outcomes in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

Tea is a widely consumed plant-derived beverage with potential metabolic and vascular effects, but its prognostic dose–response relationship in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. We analyzed 360,548 UK Biobank participants, including 169,241 individuals with MAS...

Tom Ryu, Jaejun Lee, Ji Won Han et al. · Frontiers in Nutrition · 0 citations

Review Aug 2026

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs, and after IPTW, HAIC remained associated with longer PFS than TKIs.

Jae-Sung Yoo, K. Tak, Hee Sun Cho et al. · Radiology · 0 citations